Findings underscore importance of prevention efforts
by Juliewf on Sat Nov 06, 2010 10:12 PM
everyone needs to research the benefits of B17 which is found in apricot kernals and apple seeds. This really does help people suffering from all sorts of cancers. My Father was diagnosed with Leukhemia and was not given much time, we sourced some apriocot kernals and he has now a clean bill of health. We also have our dog taking them as she was only give a few months after a recent diagnosis, four months on and the vet thinks it's a miracle!!! Learn about it as much as you can and also read books by Phillip Day, who has researched about it in great depths.
by harnek on Wed Dec 22, 2010 07:28 AM
How did you source apricot kernals to get the B17 from it, it also has a toxic shell i think.
by pritih on Wed Mar 09, 2011 08:39 AM
*i t has been claimed that vitamin B17 has certain medicinal properties that make it useful in the treatment as well as prevention of cancer.
* It helps in reducing the pain associated with arthritis. * Intake of vitamin B17 has been found to help lower high blood pressure.
* It helps maintain the general health and well being of a person.
* It strengthens the body's ability to resist infections like colds and flu.
by andy73 on Sun Dec 04, 2011 06:32 AM
In the seeds of fruits such as apple and apricots are concentrated sources of something called nitrilosides, also called B17, amygdalin, or laetrile. If you believe our medical establishment, nitrilosides have no effect on preventing or treating C
Taken from 1 cure 4 cancer dotcom-
Dr. Dean Burk, Director of the Cytochemistry Section of the federal government's National Cancer Institute reported that, in a series of tests on animal tissue, the (Laetrile) vitamin B-17 hadno harmful effect on normal cells, but was deadly to a cancer cell.
In another series of tests, Dr. Burk reported that Laetrile was responsible for prolonging the life of cancerous rats eighty percent longer than those in the control group that were not inoculated.
Dr. Burk was one of the foremost cancer specialists in the world. He was the recipient of the Gerhard Domagk Award for Cancer Research, the Hillebrand Award of the American Chemical Society, and the Commander Knighthood of the Medical Order of Bethlehem(Rome) founded in 1459 by Pope Pius XI. He held a Ph.D. in biochemistry earned at the University of California.
He was a Fellow of the National Research Council at the University of London, of the Kaiser Wilhelm Institute for Biology, and also Harvard. He was senior chemist at the National Cancer Institute, which he helped establish, and in 1946 became Director of the Cytochemistry Section.
He belonged to eleven scientific organizations, wrote three books relating to chemotherapy research in cancer, and was author or co-author of more than two hundred scientific papers in the field of cell chemistry.
For five years, between 1972 and 1977, Laetrile was meticulously tested at Sloan-Kettering under the direction of Dr. Kanematsu Sugiura.
Dr. Sugiura was the senior laboratory researcher at Sloan-Kettering with over 60 years experience. He had earned the highest respect for his knowledge and integrity. He was the perfect person to conduct experiments since his quest for truth blocked out anything else.
Dr. C. Chester Stock, the man in charge of Sloan-Kettering's laboratory-testing division wrote this about Dr. Sigiura, "Few, if any, names in cancer research are as widely known as Kanematsu Sugiura's… Possibly the high regard in which his work is held is best characterized by a comment made to me by a visiting investigator in cancer research from Russia."
"He said, 'When Dr. Sugiura publishes, we know we don't have to repeat the study, for we would obtain the same results he has reported.'"
The official report about Laetrile from Dr. Sigiura reads:
"The results clearly show that Amygdalin significantly inhibits the appearance of lung metastasis in mice bearing spontaneous mammary tumors and increases significantly the inhibition of the growth of the primary tumors… Laetrile also seemed to prevent slightly the appearance of new tumors… The improvement of health and appearance of the treated animals in comparison to controls is always a common observation… Dr. Sugiura has never observed complete regression of these tumors in all his cosmic experience with other chemotherapeautic agents." (A Summary of the Effect of Amygdalin Upon Spontaneous Mammary Tumors in Mice,Sloan-Kettering report, June 13, 1973.)
At a press conference, Dr. Sugiura was asked suddenly by a reporter if he stuck to his report. Dr. Sugiura clearly and boldly stated, "I stick," even though Sloan-Kettering was trying to discredit everything that he did.
Now, let us look at what is being discovered in prominent physicians' studies:
As early as 1974, there was at least twenty-six published papers written by well-known physicians who had used Laetrile in the treatment of their own patients and who have concluded that Laetrile is both safe and effective in the treatment of cancer.
Dr. Hans Nieper of West Germany, former Director of the Department of Medicine at the Silbersee Hospital in Hanover is a pioneer in the medical use of cobalt and is credited with developing theanti-cancer drug, cyclophosphamide. He is the originator of the concept of "electrolyte carriers" in the prevention of cardiac necrosis.
He was formerly the head of the Aschaffenburg Hospital Laboratory for chemical circulatory research. He is listed in "Who's Who" in World Science and has been the Director of the German Society for Medical Tumor Treatment. He is one of the world's most famous and respected cancer specialists.
During a visit to the U.S. in 1972, Dr. Nieper told news reporters, "After more than twenty years of such specialized work, I have found the nontoxic nitrilosides-that is Laetrile-far superior to any other known cancer treatment or preventative. In my opinion, it is the only existing possibility for theultimate control of cancer."
N.R. Bouziane, M.D., from Canada is former Director of Research Laboratories at St. Jeanne d'Arc Hospital in Montreal and a member of the hospital's tumor board in charge ofchemotherapy. He graduated magna cum laude in medicine from the University of Montreal. He also received a doctorate in science from the University of Montreal and St. Joseph's University, an affiliate of Oxford University in New Brunswick. He was a Fellow in chemistry and a Fellow inhematology and certified in clinical bacteriology, hematology, and biochemistry from the college. He also was Dean of the American Association of Bioanalysts.
After the first series of tests with Laetrile shortly after it was introduced, Dr. Bouziane reported:
"We always have a diagnosis based on histology [microscopic analysis of the tissue]. We have never undertaken a case without histological proof of cancer...
In our investigation, some terminal cases were so hopeless that they did not even receive what we consider the basic dose of thirty grams. Most cases, however, became ambulatory and some have in this short time resumed their normal activities on a maintenance dose." (Cancer News Journal, Jan./Apr. 1971, pg. 20)
Manuel Navarro, M.D., of the Philippines is former Professor of Medicine and Surgery at the University of Santo Tomas in Manila; an Associate Member of the National Research Council of the Philippines; a Fellow of the Philippine College of Physicians, the Philippine Society ofEndocrinology and Metabolism; and a member of the Philippine Medical Association, the Philippine Cancer Society, and many other medical groups. He has been recognized internationally as a cancer researcher and has over one hundred major scientific papers to his credit, some of which have been read before the International Cancer Congress.
In 1971 Dr. Navarro wrote:
I ... have specialized in oncology [the study of tumors] for the past eighteen years. For the same number of years I have been using Laetrile--amygdalin in the treatment of my cancer patients. During this eighteen year period I have treated a total of over five hundred patients with Laetrile & amygdalin by various routes of administration, including the oral and the I.V. The majority of my patients receiving Laetrile--amygdalin have been in a terminal state when treatment with this material commenced.
It is my carefully considered clinical judgment, as a practicing oncologist and researcher in this field, that I have obtained most significant and encouraging results with the use of Laetrile & amygdalin in the treatment of terminal cancer patients, and that these results are comparable or superior to the results I have obtained with the use of the more toxic standard cytotoxic agents. (Letter from Dr. Navarro to Mr. Andrew McNaughton, The McNaughton Foundation, dated January 8, 1971, published in the Cancer News Journal, Jan./April, 1971, pp. 19 -- 20.)
Ernesto Contreras, M.D., of Mexico has for over three decades operated the Good Samaritan Cancer Clinic (now called the Oasis Hospital) in Tijuana. He is one of Mexico's mostdistinguished medical figures. He received postgraduate training at Harvard's Children's Hospital in Boston. He has served as Professor of Histology and Pathology at the Mexican Army Medical School and as the chief pathologist at the Army Hospital in Mexico City.
Dr. Contreras was introduced to Laetrile in 1963 by a terminal cancer patient from the United States who brought it to his attention and urged him to treat her with it. The woman recovered, and Dr. Contreras began extensive investigation of its properties and use. Since that time he has treated many thousands of cancer patients, most of whom are American citizens who have been denied the freedom to use Laetrile in their own country.
Dr. Contreras has summarized his experiences with vitamin therapy as follows:
The palliative action [improving the comfort and well-being of the patient] is in about 60% of the cases. Frequently, enough to be significant, I see arrest of the disease or even regression in some of the very advanced cases. (Cancer News Journal, Jan./April, 1971, pp. 20. We must bear in mind that these are terminal patients--people who have been given up as hopeless by orthodox medicine. Fifteen percent recovery in that group is a most impressive accomplishment.)
Who are you going to believe, our government and medical establishment, or these respected doctors ?
going now to Walmart to stock up on apples
by Irishgeraldine on Thu Aug 23, 2012 03:15 PM
Hi i know a number of people taking Apricot kernals 1 lady took 50 a day when she had cancer now takes 10 a day to help prevent it coming back, i started taking them now too, They say 1 for every 10 pounds weight but im not sure, i have bought mine from the usa and they also sent me the tablets too, but im scared to take them, Drs dont know about these cures or dont want to know either , how many should i be eating a day , thanks Geraldine Ireland
by andy73 on Thu Aug 23, 2012 06:41 PM
They recommend 20-30 kernels daily when dealing with C
Regarding the tablets, as long as the ingredients are limited to a few that you know are safe, one of them being laetrile/amygdalin, they should be fine
Might be able to find information on here:
by apricotsrgood on Wed Aug 21, 2013 04:31 PM
crack the shell with a hammer or something - the edible seed like almond is inside the shell
by apricotsrgood on Wed Aug 21, 2013 04:32 PM
On Dec 22, 2010 7:28 AM harnek wrote: How did you source apricot kernals to get the B17 from it, it also has a toxic shell i think.
On Dec 22, 2010 7:28 AM harnek wrote:
Crack the shell with a hammer; the almond like edible seed is inside the shell. Crush the seed and put it on your salad.
When you track a discussion, you will get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to track this discussion?
If you stop tracking this discussion, you will no longer get notified by e-mail if anyone else posts a new message on this discussion. Are you sure you want to stop tracking this discussion?
If you were considering traveling for cancer treatment, which headline would you find more interesting?
Destination: HOPE. Cancer care that is worth the trip.
Over 84% of our patients travel to our hospital from another state
Neither headline is interesting
We care about your feedback. Let us know how we can improve your CancerCompass experience.